Jupiter Neurosciences Advances Parkinson’s Trial with JOTROL™ Enrollment
Event summary
- Patient enrollment begins in Phase 2a RESET trial for JOTROL™ in Parkinson’s Disease, with first dosing expected soon.
- Trial is a multi-center, randomized, double-blind, placebo-controlled study with 30 patients across three study centers.
- JOTROL™ demonstrated 9-fold higher plasma bioavailability vs. conventional resveratrol in Phase 1 trials.
- No serious adverse events reported in completed Phase 1 study with 24 healthy volunteers.
- Jupiter Neurosciences has entered a term sheet to acquire ALA-002 from PharmAla Biotech, strengthening its CNS pipeline.
The big picture
Jupiter Neurosciences is addressing a significant unmet need in the Parkinson’s Disease market, which lacks approved disease-modifying therapies. The Phase 2a RESET trial for JOTROL™ represents a critical operational milestone, positioning the company to potentially differentiate itself in a growing market projected to reach $7.58 billion by 2030. The strategic acquisition of ALA-002 further strengthens Jupiter’s pipeline in the evolving landscape of CNS therapies.
What we're watching
- Trial Execution
- Whether the Phase 2a RESET trial can maintain momentum and deliver preliminary data by H1 2027.
- Regulatory Pathway
- How the FDA’s administrative clearance for JOTROL™ may influence future approval prospects.
- Pipeline Expansion
- The pace at which the acquisition of ALA-002 from PharmAla Biotech will integrate into Jupiter’s CNS portfolio.
Related topics